Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS logo

Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS (CASA)

Market Closed
10 Aug, 15:00
XIST XIST
70. 95
-0.5
-0.6998%
408.25M Market Cap
18.14 P/E Ratio
0.82% Div Yield
10,702 Volume
0 Eps
71.45
Previous Close
Add Transaction
Day Range
70.95 71.55
Year Range
66 140.7
Want to track CASA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CASA closed today lower at ₺70.95, a decrease of -0.6998% from yesterday's close, completing a monthly decrease of -8.5696% or -₺6.65. Over the past 12 months, CASA stock lost -34.9083%.
CASA is not paying dividends to its shareholders.
Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS has completed 1 stock splits, with the recent split occurring on Dec 27, 2012.
The company's stock is traded on one exchange.

CASA Chart

People also search for

Sumas Suni Tahta ve Mobilya A.Ş.
296
+2.7778%

Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS (CASA) FAQ

What is the stock price today?

The current price is ₺70.95.

On which exchange is it traded?

Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS is listed on XIST.

What is its stock symbol?

The ticker symbol is CASA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.82%.

What is its market cap?

As of today, the market cap is 408.25M.

Has Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS ever had a stock split?

Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS had 1 splits and the recent split was on Dec 27, 2012.

Casa Emtia Petrol Kimyevi ve Sanayi Ticaret AS Profile

Oil, Gas & Consumable Fuels Industry
Energy Sector
Dr. Liisa Hurme Ph.D. CEO
XIST Exchange
TREKRSS00014 ISIN
DE Country
3,867 Employees
31 Dec 2021 Last Dividend
27 Dec 2012 Last Split
- IPO Date

Overview

Orion Oyj is a prominent pharmaceutical company that engages in the development, manufacturing, and marketing of human and veterinary pharmaceuticals, alongside active pharmaceutical ingredients (APIs). Established in 1917, the company has a global presence with operations spanning Finland, Scandinavia, the rest of Europe, North America, and other international markets. Orion Oyj's product portfolio includes prescription drugs, self-care products, and veterinary drugs, as well as providing contract manufacturing services. The company has formed strategic partnerships, such as with Propeller Health to integrate its Easyhaler(R) product portfolio and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. Its headquarter is located in Espoo, Finland.

Products and Services

  • Prescription Drugs and Self-care Products

    Orion Oyj offers an array of medications for a variety of conditions. Nubeqa is targeted for prostate cancer treatment, Precedex, Dexdor, and Precedex for sedation in medical procedures, and Burana for inflammatory pain. The Divina series addresses menopausal symptoms, Trexan for rheumatoid arthritis and cancer, and Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease. In addition, Biosimilars provide alternatives for rheumatoid arthritis and inflammatory bowel diseases, Simdax treats acute decompensated heart failure, and Fareston for breast cancer. Orion also offers solutions for asthma and chronic obstructive pulmonary disease (COPD) with its Easyhaler products like Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol.

  • Veterinary Drugs

    For animal health, Orion develops and markets a range of medications including Bonqat for feline hypertension, Clevor for induced vomiting in dogs, and a selection of sedatives and anesthetics such as Domosedan, Domitor, Antisedan, Dexdomitor, and Domosedan Gel. Sileo, designed for noise aversion in dogs, and Tessie, address other veterinary needs. Orion also acts as a distributor for veterinary drugs produced by other global companies, broadening its portfolio.

  • Active Pharmaceutical Ingredients (APIs)

    Orion Oyj supplies APIs for both generic compounds and proprietary products. Through its sophisticated manufacturing capabilities, the company provides contract manufacturing services to partners globally, specializing in high-quality pharmaceutical ingredients.

  • Partnerships and Collaborations

    Noteworthy partnerships include the collaboration with Propeller Health to integrate smart technology with Orion’s Easyhaler(R) line for improved treatment of respiratory conditions. Furthermore, Orion's agreement with Amneal Pharmaceuticals, Inc. facilitates the commercialization of Amneal's generic products, expanding Orion's portfolio and strengthening its market position.

Contact Information

Address: Orionintie 1A, Espoo, Finland, 02200
Phone: 358 10 4261